First Time Loading...

BioCardia Inc
NASDAQ:BCDA

Watchlist Manager
BioCardia Inc Logo
BioCardia Inc
NASDAQ:BCDA
Watchlist
Price: 0.368 USD -3.03% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

BCDA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. [ Read More ]

The intrinsic value of one BCDA stock under the Base Case scenario is 2.763 USD. Compared to the current market price of 0.368 USD, BioCardia Inc is Undervalued by 87%.

Key Points:
BCDA Intrinsic Value
Base Case
2.763 USD
Undervaluation 87%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BioCardia Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BCDA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
BioCardia Inc

Provide an overview of the primary business activities
of BioCardia Inc.

What unique competitive advantages
does BioCardia Inc hold over its rivals?

What risks and challenges
does BioCardia Inc face in the near future?

Has there been any significant insider trading activity
in BioCardia Inc recently?

Summarize the latest earnings call
of BioCardia Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for BioCardia Inc.

Provide P/S
for BioCardia Inc.

Provide P/E
for BioCardia Inc.

Provide P/OCF
for BioCardia Inc.

Provide P/FCFE
for BioCardia Inc.

Provide P/B
for BioCardia Inc.

Provide EV/S
for BioCardia Inc.

Provide EV/GP
for BioCardia Inc.

Provide EV/EBITDA
for BioCardia Inc.

Provide EV/EBIT
for BioCardia Inc.

Provide EV/OCF
for BioCardia Inc.

Provide EV/FCFF
for BioCardia Inc.

Provide EV/IC
for BioCardia Inc.

Show me price targets
for BioCardia Inc made by professional analysts.

What are the Revenue projections
for BioCardia Inc?

How accurate were the past Revenue estimates
for BioCardia Inc?

What are the Net Income projections
for BioCardia Inc?

How accurate were the past Net Income estimates
for BioCardia Inc?

What are the EPS projections
for BioCardia Inc?

How accurate were the past EPS estimates
for BioCardia Inc?

What are the EBIT projections
for BioCardia Inc?

How accurate were the past EBIT estimates
for BioCardia Inc?

Compare the revenue forecasts
for BioCardia Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of BioCardia Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of BioCardia Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of BioCardia Inc compared to its peers.

Compare the P/E ratios
of BioCardia Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing BioCardia Inc with its peers.

Analyze the financial leverage
of BioCardia Inc compared to its main competitors.

Show all profitability ratios
for BioCardia Inc.

Provide ROE
for BioCardia Inc.

Provide ROA
for BioCardia Inc.

Provide ROIC
for BioCardia Inc.

Provide ROCE
for BioCardia Inc.

Provide Gross Margin
for BioCardia Inc.

Provide Operating Margin
for BioCardia Inc.

Provide Net Margin
for BioCardia Inc.

Provide FCF Margin
for BioCardia Inc.

Show all solvency ratios
for BioCardia Inc.

Provide D/E Ratio
for BioCardia Inc.

Provide D/A Ratio
for BioCardia Inc.

Provide Interest Coverage Ratio
for BioCardia Inc.

Provide Altman Z-Score Ratio
for BioCardia Inc.

Provide Quick Ratio
for BioCardia Inc.

Provide Current Ratio
for BioCardia Inc.

Provide Cash Ratio
for BioCardia Inc.

What is the historical Revenue growth
over the last 5 years for BioCardia Inc?

What is the historical Net Income growth
over the last 5 years for BioCardia Inc?

What is the current Free Cash Flow
of BioCardia Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for BioCardia Inc.

Financials

Balance Sheet Decomposition
BioCardia Inc

Current Assets 1.5m
Cash & Short-Term Investments 1.1m
Receivables 63k
Other Current Assets 295k
Non-Current Assets 1.5m
PP&E 1.4m
Other Non-Current Assets 171k
Current Liabilities 3.6m
Accounts Payable 890k
Accrued Liabilities 2.1m
Other Current Liabilities 632k
Non-Current Liabilities 982k
Other Non-Current Liabilities 982k
Efficiency

Earnings Waterfall
BioCardia Inc

Revenue
477k USD
Operating Expenses
-12.1m USD
Operating Income
-11.6m USD
Other Expenses
73k USD
Net Income
-11.6m USD

Free Cash Flow Analysis
BioCardia Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BCDA Profitability Score
Profitability Due Diligence

BioCardia Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 3-Years Revenue Growth
ROIC is Increasing
Negative 1-Year Revenue Growth
25/100
Profitability
Score

BioCardia Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

BCDA Solvency Score
Solvency Due Diligence

BioCardia Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
40/100
Solvency
Score

BioCardia Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BCDA Price Targets Summary
BioCardia Inc

There are no price targets for BCDA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BCDA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BCDA Price
BioCardia Inc

1M 1M
-12%
6M 6M
-6%
1Y 1Y
-82%
3Y 3Y
-90%
5Y 5Y
-96%
10Y 10Y
-96%
Annual Price Range
0.368
52w Low
0.36
52w High
2.85
Price Metrics
Average Annual Return -26.4%
Standard Deviation of Annual Returns 31.75%
Max Drawdown -98%
Shares Statistics
Market Capitalization 9.8m USD
Shares Outstanding 26 732 500
Percentage of Shares Shorted 2.33%

BCDA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

BioCardia Inc Logo
BioCardia Inc

Country

United States of America

Industry

Biotechnology

Market Cap

9.8m USD

Dividend Yield

0%

Description

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. The company is headquartered in Sunnyvale, California and currently employs 28 full-time employees. The company is focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Its lead therapeutic candidates are based on the CardiAMP Cell Therapy System, a platform which provides an autologous bone marrow-derived cell therapy for treatment in two clinical indications, such as ischemic heart failure and refractory angina resulting from chronic myocardial ischemia. Its second therapeutic platform is an investigational bone marrow derived allogeneic off-the shelf Neurokinin-1 Receptor Positive mesenchymal stem cell (MSC) therapy for the treatment of cardiac and pulmonary disease. The company has three enabling device product lines: the CardiAMP cell processing system, the Helix biotherapeutic delivery system (Helix), and the Morph vascular access product line (Morph). The company is advancing therapeutic candidates for heart failure, chronic myocardial infarction, and acute respiratory distress syndrome.

Contact

CALIFORNIA
Sunnyvale
320 Soquel Way
+16502260120.0
http://www.biocardia.com/

IPO

1996-11-13

Employees

28

Officers

CEO, President & Director
Dr. Peter A. Altman Ph.D.
Chief Financial Officer
Mr. David McClung
Senior Vice President of Devices
Mr. Edward M. Gillis
Chief Medical Officer and VP of Clinical & Regulatory
Dr. Sujith Shetty MBBS

See Also

Discover More
What is the Intrinsic Value of one BCDA stock?

The intrinsic value of one BCDA stock under the Base Case scenario is 2.763 USD.

Is BCDA stock undervalued or overvalued?

Compared to the current market price of 0.368 USD, BioCardia Inc is Undervalued by 87%.